Medicine:Omegaven
Omegaven is a fatty acid emulsion produced by Fresenius Kabi. It is used for total parenteral nutrition (feeding directly into a venous catheter), e.g. in short bowel syndrome. It is rich in omega-3 fatty acids. It has gained popularity in children in preference to the more commonly used Intralipid after case reports that it reduced the risk of liver damage.[1]
A recent study indicated that the use of Omegaven may be an appropriate intervention strategy for newborns with a very low birth weight, gastrochisis, and jejunal atresia.[2]
It is currently undergoing a clinical trial at National Taiwan University Hospital.[3]
Although the use of Omegaven in children in the United States is experimental, the use of it in adults in Europe is less controversial.[4] In European studies, Omegaven has been associated with a reduction in psoriasis, when contrasted to administration of omega-6 fatty acid Lipoven.[5] Omegaven has also been associated with reduced mortality and antibiotic use during hospital stays.[6]
Omegaven was approved for use in the United States on, July 27, 2018, and is now available to patients on the US market by prescription effective November 15, 2018.[7]
References
- ↑ "Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management". Pediatrics 118 (1): e197–201. 2006. doi:10.1542/peds.2005-2662. PMID 16818533.
- ↑ "Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease". Journal of Perinatology 27 (5): 284–90. 2007. doi:10.1038/sj.jp.7211686. PMID 17344923.
- ↑ Clinical trial number NCT00172198 at ClinicalTrials.gov
- ↑ A Doctor's Push For Drug Pits Him Against Its Maker at Wall Street Journal
- ↑ "n-3 fatty acids in psoriasis". Br. J. Nutr.. 87 Suppl 1: S77–82. 2002. doi:10.1079/bjn2001459. PMID 11895157.
- ↑ "Omega-3 fatty acids improve the diagnosis-related clinical outcome". Crit. Care Med. 34 (4): 972–9. 2006. doi:10.1097/01.CCM.0000206309.83570.45. PMID 16484909.
- ↑ Research, Center for Drug Evaluation and. "Investigational New Drug (IND) Application - How to request Omegaven for Expanded Access Use" (in en). https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm368740.htm.
External links
- Cooke, Robert (2006-07-03). "How fish oil may have saved babies' lives". The Boston Globe. http://www.boston.com/news/globe/health_science/articles/2006/07/03/how_fish_oil_may_have_saved_babies_lives/. Retrieved 2007-08-22.
- "Fishing for the Right Solution" at Children's Hospital Boston
- "The Right Kind of Oil" at Children's Hospital Boston
- Team on a Mission at Toronto Star
- Old Fashioned Lifeline Boston Globe 1/9/2009
- rockcenter.nbcnews.com: drug treatment omegaven that could save infants lives not yet approved by fda
- US approval in pediatric patients
- [1]
 |
